← Back to Search

CAR T-cell Therapy

Descartes-11 for Multiple Myeloma

Phase 1 & 2

Waitlist Available

Research Sponsored by Cartesian Therapeutics

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Adequate vital organ function

Active multiple myeloma that is refractory after at least 2 prior lines of therapy

Timeline

Screening 3 weeks

Treatment Varies

Follow Up time frame: 1, 3, 6, 9 and 12 months

Awards & highlights

Study Summary

This trial will test how safe and effective a new treatment is for multiple myeloma. The treatment involves using a person's own immune cells to fight the cancer.

Who is the study for?

This trial is for people with active multiple myeloma who have tried at least two other treatments without success. They must have measurable disease signs and their vital organs should be functioning well. They cannot join if they currently have an infection.Check my eligibility

What is being tested?

The study is testing Descartes-11, which are modified immune cells targeting cancer, along with Fludarabine and Cyclophosphamide drugs in patients with multiple myeloma to see how safe it is and how well it works against the cancer.See study design

What are the potential side effects?

Potential side effects may include reactions related to the immune system attacking normal cells, symptoms from cell infusion, low blood counts due to chemotherapy agents like Fludarabine and Cyclophosphamide, as well as increased risk of infections.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

You have multiple myeloma that has not responded to at least two previous treatments.

Select...

You do not have any current infections.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ time frame: 1, 3, 6, 9 and 12 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~time frame: 1, 3, 6, 9 and 12 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and time frame: 1, 3, 6, 9 and 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Incidence (number) of Treatment-Emergent Adverse Events

Secondary outcome measures

Treatment Response

Trial Design

1Treatment groups

Experimental Treatment

Group I: Dose-EscalationExperimental Treatment3 Interventions

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Fludarabine

2012

Completed Phase 3

~1080

Cyclophosphamide

1995

Completed Phase 3

~3770

0 / 3Eligibility criteria met

Find a Location

Who is running the clinical trial?

Cartesian TherapeuticsLead Sponsor

8 Previous Clinical Trials

223 Total Patients Enrolled

5 Trials studying Multiple Myeloma

133 Patients Enrolled for Multiple Myeloma

Media Library

Descartes-11 (CAR T-cell Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT03994705 — Phase 1 & 2

Multiple Myeloma Research Study Groups: Dose-Escalation

Multiple Myeloma Clinical Trial 2023: Descartes-11 Highlights & Side Effects. Trial Name: NCT03994705 — Phase 1 & 2

Descartes-11 (CAR T-cell Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03994705 — Phase 1 & 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Do you know of any other research studies that have used Descartes-11?

"The first Descartes-11 study was completed over two decades ago, in 1997. Since then, there have been 1271 similar studies. Right now, 928 studies are still active. The majority of these are based in Madison, Wisconsin."

Answered by AI

What is the primary condition that Descartes-11 is effective in treating?

"Descartes-11 is often used to ameliorate symptoms in multiple sclerosis patients. It has also been found to be useful in treating mixed-cell type lymphoma, leukemia, myelocytic, acute, and retinoblastoma."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Descartes-11 in Multiple Myeloma

2019. "Descartes-11 in Multiple Myeloma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03994705.

All > Scar